Holly Bernal, NP
Nurse Practitioner · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Holly Bernal’s office at (650) 497-8000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence C11097 · Cancelled
Licence status: Cancelled · since 1948 · Hahnemann University School of Medicine.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
$4,738,222
Pharmacies billed $4,738,222 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 115) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
74 generic and 41 brand-name prescriptions · $4,738,222 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ravicti | 29 | $4,335,006 | $149,483 |
| Sapropterin Dihydrochloride | 32 | $248,530 | $7,767 |
| Palynziq | 12 | $151,303 | $12,609 |
| Levocarnitine | 14 | $1,729 | $124 |
| Famotidine | 12 | $73 | $6 |
Year by year
| 2024 | 115 | 11 | 0% (0) | 36% | $4,738,222 |
| 2023 | 123 | None | 0% (0) | 37% | $5,014,422 |
| 2022 | 105 | None | 0% (0) | 50% | $4,631,559 |
| 2021 | 115 | None | 0% (0) | 71% | $4,330,467 |
| 2020 | 80 | None | 0% (0) | 76% | $2,322,571 |
| 2019 | 43 | None | 0% (0) | 84% | $3,631,670 |
| 2018 | 47 | None | 0% (0) | 96% | $3,891,748 |
| 2017 | 46 | None | 0% (0) | 96% | $3,105,255 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Ravicti | 27 | $4,594,601 | $170,170 |
| Sapropterin Dihydrochloride | 26 | $234,578 | $9,022 |
| Palynziq | 13 | $158,768 | $12,213 |
| Leucovorin | 18 | $6,391 | $355 |
| Levocarnitine | 13 | $1,826 | $140 |
| Famotidine | 12 | $125 | $10 |
2022: 6 drugs
| Ravicti | 27 | $4,282,826 | $158,623 |
| Sapropterin Dihydrochloride | 20 | $184,408 | $9,220 |
| Palynziq | 11 | $158,471 | $14,406 |
| Levocarnitine | 12 | $2,962 | $247 |
| Levocarnitine | 13 | $1,845 | $142 |
| Leucovorin | 13 | $706 | $54 |
2021: 5 drugs
| Ravicti | 25 | $4,073,657 | $162,946 |
| Palynziq | 19 | $249,093 | $13,110 |
| Leucovorin | 16 | $3,260 | $204 |
| Levocarnitine | 11 | $1,588 | $144 |
| Water | 25 | $66 | $3 |
2020: 4 drugs
| Ravicti | 16 | $1,937,322 | $121,083 |
| Palynziq | 19 | $313,956 | $16,524 |
| Leucovorin | 13 | $4,457 | $343 |
| Levocarnitine | 12 | $3,048 | $254 |
2019: 1 drug
| Ravicti | 28 | $3,588,604 | $128,164 |
2018: 1 drug
| Ravicti | 39 | $3,890,334 | $99,752 |
2017: 2 drugs
| Ravicti | 33 | $3,101,914 | $93,997 |
| Levocarnitine | 11 | $3,338 | $303 |
Money from drug and device companies
$13,928 in 2025
| 2025 | 7 | 31 | $9,688 | $13,928 |
| 2024 | 7 | 82 | $23,269 | $34,379 |
| 2023 | 2 | 2 | $2,205 | $2,205 |
| 2022 | 4 | 24 | $4,860 | $8,708 |
| 2021 | 3 | 8 | $2,633 | $4,212 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| BioMarin Pharmaceutical | Palynziq | $6,766 | 9 payments
|
| Ultragenyx Pharmaceutical | Dojolvi | $3,809 | 9 payments
|
| PTC Therapeutics | Sephience | $2,347 | 9 payments
|
| Amgen | None | $590 | 1 payment
|
| Medunik USA | Pheburane | $200 | 1 payment
|
| Chiesi USA | Elfabrio | $115 | 1 payment
|
See all 31 published payments
| Cycle Pharmaceuticals | Meals · 2025-12-04 | Javygtor | $100 |
| Chiesi USA | Meals · 2025-09-19 | Elfabrio | $115 |
| PTC Therapeutics | Meals · 2025-09-18 | Sephience | $196 |
| BioMarin Pharmaceutical | Meals · 2025-09-17 | None | $124 |
| Medunik USA | Consulting · 2025-09-15 | Pheburane | $200 |
| BioMarin Pharmaceutical | Paid to speak or teach · 2025-09-05 | Palynziq | $2,125 |
| PTC Therapeutics | Meals · 2025-09-04 | None | $43 |
| BioMarin Pharmaceutical | Travel · 2025-08-20 | Palynziq | $122 |
| BioMarin Pharmaceutical | Travel · 2025-08-20 | Palynziq | $593 |
| BioMarin Pharmaceutical | Travel · 2025-08-20 | Palynziq | $1,017 |
| BioMarin Pharmaceutical | Travel · 2025-08-20 | Palynziq | $170 |
| BioMarin Pharmaceutical | Meals · 2025-08-20 | Palynziq | $17 |
| BioMarin Pharmaceutical | Paid to speak or teach · 2025-07-03 | Palynziq | $1,598 |
| Ultragenyx Pharmaceutical | Paid to speak or teach · 2025-07-01 | None | $250 |
| Amgen | Consulting · 2025-06-10 | None | $590 |
| Ultragenyx Pharmaceutical | Paid to speak or teach · 2025-06-02 | Dojolvi | $500 |
| Ultragenyx Pharmaceutical | Travel · 2025-05-02 | Dojolvi | $156 |
| Ultragenyx Pharmaceutical | Paid to speak or teach · 2025-05-02 | Dojolvi | $2,125 |
| Ultragenyx Pharmaceutical | Meals · 2025-05-02 | Dojolvi | $35 |
| BioMarin Pharmaceutical | Paid to speak or teach · 2025-04-09 | Palynziq | $1,000 |
| Ultragenyx Pharmaceutical | Travel · 2025-03-28 | Dojolvi | $316 |
| Ultragenyx Pharmaceutical | Travel · 2025-03-28 | Dojolvi | $226 |
| Ultragenyx Pharmaceutical | Travel · 2025-03-28 | Dojolvi | $80 |
| Ultragenyx Pharmaceutical | Meals · 2025-03-27 | Dojolvi | $122 |
| PTC Therapeutics | Travel · 2025-03-18 | None | $68 |
| PTC Therapeutics | Travel · 2025-03-18 | None | $75 |
| PTC Therapeutics | Consulting · 2025-03-18 | None | $1,300 |
| PTC Therapeutics | Travel · 2025-03-17 | None | $378 |
| PTC Therapeutics | Travel · 2025-03-17 | None | $163 |
| PTC Therapeutics | Meals · 2025-03-17 | None | $57 |
| PTC Therapeutics | Meals · 2025-03-17 | None | $68 |
See earlier years (2024, 2023, 2022, 2021)
2024: $34,379
| Ultragenyx Pharmaceutical | Dojolvi | $18,655 | 40 payments
|
| Amgen | Ravicti | $5,345 | 11 payments
|
| Genzyme | Fabrazyme | $4,696 | 10 payments
|
| PTC Therapeutics | None | $2,996 | 14 payments
|
| Zevra Therapeutics | Olpruva | $1,400 | 1 payment
|
| Medunik USA | Pheburane | $1,000 | 1 payment
|
| BioMarin Pharmaceutical | Palynziq | $287 | 3 payments
|
2023: $2,205
| Cycle Pharmaceuticals | Nityr | $1,125 | 1 payment
|
| Horizon Therapeutics plc | Ravicti | $1,080 | 1 payment
|
2022: $8,708
| Horizon Therapeutics plc | Ravicti | $8,487 | 21 payments
|
| Genzyme | Fabrazyme | $100 | 1 payment
|
| BioMarin Pharmaceutical | Palynziq | $100 | 1 payment
|
| Ultragenyx Pharmaceutical | Dojolvi | $21 | 1 payment
|
2021: $4,212
| Horizon Therapeutics plc | Ravicti | $3,979 | 3 payments
|
| BioMarin Pharmaceutical | Palynziq | $142 | 2 payments
|
| Ultragenyx Pharmaceutical | Dojolvi | $90 | 3 payments
|
Professional record
- NPI
- 1205292133
- Licence
- CA 11097, CA 456433California C11097: Cancelled
More record details
- Sole proprietor
- No
- Taxonomy
- Nurse practitioner (363L00000X); Federal specialty code 363LF0000X (363LF0000X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2016-01-07
- NPI last updated
- 2023-03-28
- NPI record certified
- 2023-03-28
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Palo Alto, CA, 94305